Past Winner Spotlight: ENDV, PPCH, EYES, LPCN, GALE

WINDSOR, ONTARIO / ACCESSWIRE / February 29, 2016 / The Wealthy Biotech Trader (or "WBT"), an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known biotech, pharmaceutical and medical device stocks releasing impressive news and making market moves, would like to highlight a few of our past winners mentioned in our articles over the past year.

We will get into the details below, but first, here is our list:

1) Endonovo Therapeutics, Inc. (OTCQB: ENDV)
2) Propanc Health Group (OTCQB: PPCH)
3) Second Sight Medical Products, Inc. (NASDAQ: EYES)
4) Lipocine Inc. (NASDAQ: LPCN)
5) Galena Biopharma, Inc. (NASDAQ: GALE)

For biotech investing, 2015 was a year of heartbreak: valuations shrunk, many Companies are now trading for less than the value of the cash they have in the bank and M&A / IPO's have come to screeching halt.

Over the past 12 months the NASDAQ Biotech Index ETF (NASDAQ: IBB) has been brought down well into bear territory with a loss of 23%. Most chart readers knew this retracement, or pause, was coming and are calling it healthy. After all, it has had a 6 year, 400% run. At WBT we feel that we are near a bottom as the S&P 500 finds its feet somewhere in the 1,750 range. We also feel that once the overall market stabilizes, large pharma companies will be on the look-out for great bargains in the small caps in the form of acquisitions and joint ventures. If it plays out like this, we will again be in a secular bull market for healthcare—one place Investors feel safer since the price of one's health is non-discretionary—and taken care of by the government even in the worst of economic times.

Whatever the global economy does going forward, the facts are global healthcare spending will not stray much from the projected $9.3 Trillion in 2018 (2015 Global Healthcare Outlook, Deloitte.), and innovative companies investing more effective, less costly and safer ways to treat patients will always have a healthy bottom line.

A few of our favorite companies written about over the past 12 months made some healthy gains after our mention and here is a high-level overview:

First and foremost Endonovo Therapeutics, Inc. (OTCQB: ENDV) is an innovative biotechnology company developing a bioelectronic device and therapies for regenerative medicine to help heal the body more effectively and prevent organ rejection.

After announcing Endonovo (OTCQB: ENDV) to Investors on Twitter and Facebook in the middle of December, the stock took off from a low of $0.17 and ran to $0.81 at the beginning of February, locking in potential gains of 375% for investors in only 32 trading days.

Endonovo's Immunotronic technology was originally developed at NASA to treat injury and diseases astronauts may encounter during long-term missions using "time varying electromagnetic fields". The non-implantable bioelectronic device ENDV has for potentially treating/preventing vital organ failure through the reduction of inflammation and the promotion of regeneration has been designed to be completely safe and non-invasive. Endonovo's other technology, the Cytotronic platform, provides for a method of expanding and enhancing cells using simulated microgravity and Time-Varying Electromagnetic Fields (TVEMF) for cell therapies which the company intends to utilize in the treatment of graft versus host disease.

This name is one to keep on your radars for 2016 as they now appear to have the trading volume typically looked for by institutional Investors in order to come into a stock for a decent sized investment; exactly what ENDV needs to get their news train rolling, as both of their technologies are ready for development, but just needed the capital to do so. With this development would come news, and if the news is positive the stock should appreciate it.

Just that happened last year for Propanc Health Group (OTCQB: PPCH). When we first mentioned the company PPCH was a sub-penny stock trading at around $0.004-- fast forward a few months and the ticker was up +3,400% to over $0.13. Congrats to everyone on the winning side of this.

After a significant uptick in investor interest and stock price, the company secured several series' of funding from multiple sources, thus allowing the company's R&D to progress, which was subsequently followed by a series of positive press releases.

Keep this name on your radar as they approach clinical trials, which they have stated would happen "…late 2016, or early 2017." And as they meet with the European Regulatory Agency this quarter to discuss a development pathway for their lead product "PRP," a potential cancer/ cancer stem cell killing compound. The Company has stated they are fully funded for the rest of the year with a cash runway covering up to and potentially including some of their human clinical work.

Second Sight Medical Products, Inc. (NASDAQ:EYES) is truly a remarkable company with its mission is to develop, manufacture and market innovative implantable visual prosthetics to enable blind individuals to achieve greater independence. Who would have ever thought the blind could have a chance to see again? Not many. This type of technology is beyond unique-- Some may even call it futuristic.

EYES's technology is not for all blind people, but for the individuals who lost their vision due to retinitis pigmentosa (RP) which severely damages the photoreceptors in our eyes. Second Sight has already developed and has started manufacturing the Argus® II Retinal Prosthesis System.

Last week the company was mentioned they were going to be featured on HBO's VICE series which had Investors bidding up the stock to highs of 6.93. WBT mentioned EYES on January 29th, 2016—from the low after that to the high reached last Tuesday, Investors could have banked gains of around 75%-- not bad for 17 days!

Lipocine Inc. (NASDAQ: LPCN) is a specialty pharmaceutical company focused on developing innovative oral treatment alternatives for use in men's and women's health using its proprietary drug delivery technologies. Lipocine product development pipeline entails repositioning of established drugs with significantly improved patient compliance through an efficient 505(b) (2) regulatory pathway strategy.

When we first mentioned LPCN on August 27th, 2015 the stock was trading at $13.36, a short 10 trading days later the stock hit a high of $19.23—a handsome 44% return on investment.

Galena Biopharma, Inc. (NASDAQ: GALE) is a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs. Galena's development portfolio is focused primarily on addressing the rapidly growing patient populations of cancer survivors by harnessing the power of the immune system to prevent cancer recurrence.

When WBT first mentioned GALE it was May 6th, 2015 when trading at $1.35. Roughly a month later the stock found its way to $2.39 for a modest gain of 77%-- or a whopping 900% when you annualize those numbers!

As we stated before, the year ahead is not without its challenges, but we feel the best spot for any market condition is in healthcare. Follow us below (Twitter, Facebook, Email, Text Message alerts) to stay in the game and know when we announce new trade ideas.

The Wealthy Biotech Trader is always researching new trade ideas which have the makings for large market moves. Traders are urged to follow our parent outlet, The Wealthy Venture Capitalist on social media (see below) to stay apprised. We are an anti-email media outlet, and as such will only be releasing our reports/ updates/ news through Text Message Alerts, Twitter and Facebook.


Email us with questions:

Follow us on Twitter: @Wealthy_VC
Like us on Facebook:
To receive text Message alerts on new articles:

This report/release/profile is a commercial advertisement and is for general information and entertainment purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below. The Wealthy Biotech Trader and its employees are not a Registered Investment Advisors, Broker Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The Wealthy Biotech Trader encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and The Wealthy Biotech Trader makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. The Private Securities Litigation Reform Act of 1995 provides investors a 'safe harbor' in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be "forward looking statements". Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as "projects", "foresee", "expects", "will", "anticipates", "estimates", "believes", "understands", or that by statements indicating certain actions "may", "could", or "might" occur. Understand there is no guarantee past performance will be indicative of future results. The Wealthy Biotech Trader's controlling parent company has been compensated $150,000 by Endonovo Therapeutics, Inc. in the form of a convertible note and readers should understand that they will convert this note into common shares sell them into the market as soon as the statutory 144 hold period has lapsed. The Wealthy Biotech Trader's parent company has been and will be compensated $10,000 per month, has also been compensated $60,000 in the form of a convertible promissory note, as well as 4 million restricted shares by Propanc Heath Group and readers should understand that they will convert this note and restricted shares into free trading common shares and sell them into the market as soon as the statutory 144 hold period has lapsed. Readers must visit our website at in order to view our entire disclaimer which covers most of the risks, biases and liability releases to have a full understanding after reading this article.

SOURCE: The Wealthy Biotech Trader

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.